Background. Although prophylactic central neck dissection (pCND) may reduce future locoregional recurrence after total thyroidectomy (TT) for low-risk papillary thyroid carcinoma (PTC), it is associated with a higher initial morbidity. We aimed to compare the long-term costeffectiveness between TT with pCND (TT?pCND) and TT alone in the institution's perspective. Methods. Our case definition was a hypothetical cohort of 100,000 nonpregnant female patients aged 50 years with a 1.5-cm cN0 PTC within one lobe. A Markov decision tree model was constructed to compare the estimated costeffectiveness between TT?pCND and TT alone after a 20-year period. Outcome probabilities, utilities, and costs were estimated from the literature. The threshold for costeffectiveness was set at US$50,000 per quality-adjusted life year (QALY). Sensitivity and threshold analyses were used to examine model uncertainty. Results. Each patient who underwent TT?pCND instead of TT alone cost an extra US$34.52 but gained an additional 0.323 QALY. In fact, in the sensitivity analysis, TT?pCND became cost-effective 9 years after the initial operation. In the threshold analysis, none of the scenarios that could change this conclusion appeared clinically possible or likely. However, TT?pCND became cost-saving (i.e., less costly and more cost-effective) at 20 years if associated permanent vocal cord palsy was kept B1.37 %, permanent hypoparathyroidism was B1.20 %, and/or postoperative radioiodine ablation use was B73.64 %.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma, with its incidence doubled over the last two decades. [1] [2] [3] [4] However, despite good prognosis, locoregional recurrence (LR) is relatively common after curative surgery. 5 With recognition of the step-wise progression of metastasis from central (level VI) to lateral (levels II-V) compartments, routine prophylactic central neck dissection (pCND) has been advocated at the time of total thyroidectomy (TT) to minimize LR. [6] [7] [8] Although central neck dissection (CND) is indicated in clinically nodal-positive disease, it remains controversial in clinically nodal-negative disease (cN0). 9 There is little evidence to suggest that patients with cN0 PTC would benefit from pCND at the time of TT (TT?pCND). Although a recent meta-analysis reported a 35 % reduction in LR in the TT?pCND group, it was at the expense of higher morbidity. 10 Given that conducting an adequately powered prospective, randomized trial comparing outcomes between TT?pCND and TT alone is unlikely in the near future and that cost-effectiveness is an important outcome measurement between two different procedures or strategies, we aimed to determine which is a more cost-effective strategy in the long-term. 11 To our knowledge, there has only been one study which specifically compared the cost-effectiveness between the two surgical strategies. 12 It concluded that TT?pCND was less cost-effective than TT alone. 12 However, the literature search was limited, and the quality adjustment factors used came from nonthyroid disease. Furthermore, as acknowledged by the authors, some operative complications were omitted, and that omission might have favored the TT-alone strategy. 12 Given these findings, we used a decision-tree analysis model to compare the medium-to long-term cost-effectiveness between the two strategies, namely, TT?pCND and TT alone, in a reference population with biopsy-proven cN0 PTC.
METHODS

Case Definition
A hypothetical cohort of 100,000 nonpregnant female patients aged 50 years with a unifocal intrathyroidal 1.5-cm cN0 PTC and with no previous thyroidectomy or neck irradiation was simulated in the model.
The Model
A decision tree model using TreeAge Software Pro version 2013 (Treeage Software, Inc., Williamstown, MA) was constructed to compare the estimated long-term costeffectiveness between TT?pCND and TT alone. See Appendix in Fig. 3 outlines the Markov decision model over 1 year. Patients underwent one of two surgical strategies, namely, TT?pCND or TT alone, and were followed up until death or 70 years old, whichever came earlier. The model included 3 major health states after primary operation, namely, disease-free, alive with LR, and death. In case of LR involving the central, lateral, or central and lateral compartments, a compartment-oriented reoperation, and radioiodine (RAI) were offered. Patients in either strategy may experience one of the surgical complications from the primary operation or reoperation.
Probabilities
Estimates of complications from the primary operation, postoperative RAI, and central and/or lateral recurrences after the primary operation came from the available literature. 8, 9, 18, 19, [23] [24] [25] [26] [27] [28] [29] Studies were limited to those which directly compared outcomes between the two strategies in cN0 PTC. Estimates of complications from reoperation and death from nonthyroid causes came from separate PubMed literature searches. [13] [14] [15] [16] [17] [18] [19] Base-case values were derived by pooling the results of all retrieved studies. The annual mortality rate of female patients by 10-year age groups was quoted from the US Centers for Disease Control and Prevention. 20 Table 1 summarizes outcome probabilities used.
Cost Data
Our model only looked at the cost of two strategies from an institution's perspective. Total cost included procedural cost, complication cost, and hospitalization. Indirect costs such as loss of productivity and wages were not included. Unit costs of TT and initial pCND were estimated on the basis of Medicare reimbursement for the surgical procedure obtained from public access files from the Centers for Medicare and Medicaid Services. [21] [22] [23] Unit costs of other surgical procedures (such as reoperative CND and reoperative lateral selective neck dissection), RAI, surgically related complications, and annual routine surveillance were based on data obtained from previous cost-effectiveness analyses. 24, 25 For the reoperative cases, the procedural cost already included the cost of fine-needle aspiration. Table 1 summarizes the unit costs used.
Effectiveness Data
Effectiveness was measured by quality-adjusted life years (QALYs) gained. QALY adjusts the life expectancy through the multiplication of quality-of-life adjustment with the duration stayed at each health state. The quality-of-life adjustment is quantified by a utility score ranging from 0 to 1. Table 1 lists the utility score for each health state.
Assumptions
All pCNDs were assumed unilateral only, and surgical resection was the only option for LR involving the different compartments. The LR rates under each strategy were assumed constant throughout the life cycle. Patients were assumed suitable for and agreeable to reoperation. For simplicity, only a maximum of one LR and one reoperation per patient were allowed. Similarly, only one complication was allowed for each primary operation or reoperation. Reoperative CND was assumed bilateral, whereas reoperative lateral CND was assumed unilateral, involving levels II to V. An empirical 3-GBq RAI was given after each reoperation. The costs of preoperative assessment and surveillance were assumed to be the same in both groups. Full compliance was assumed for all kinds of assessment, treatment, and surveillance.
Base-Case Analysis
All the costs and effectiveness were discounted by an annual rate of 3 %. This was consistent with the established guidelines for cost-effectiveness analysis. 26 The only outcome measurement was the incremental cost-effectiveness ratio (ICER). The ICER was the cost difference between TT?pCND and TT alone divided by the difference in effectiveness between TT?pCND and TT alone. A positive incremental cost meant TT?pCND was more costly, whereas a positive effectiveness meant the TT?pCND was more effective. A strategy was said to be cost-saving if that strategy cost less and was more effective than the other [13] [14] [15] [16] [17] Temporary bilateral VCP/tracheostomy 0.16 0.03-4.94 [13] [14] [15] [16] [17] Permanent unilateral VCP 2.70 0.00-17.78 [13] [14] [15] [16] [17] Permanent bilateral VCP/tracheostomy 0.07 0.00-3.16 [13] [14] [15] [16] [17] Temporary hypoparathyroidism 17.14 6.06-42.22 [13] [14] [15] [16] [17] [18] Permanent hypoparathyroidism 1.70 0.00-5.00 [13] [14] [15] [16] [17] [18] Hematoma 1.10 0.00-4.35 [13] [14] [15] [16] [17] Chyle leakage 1.80 0.00-2.22 [13] [14] [15] Total morbidity a 28.71
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Sensitivity Analysis
Univariate sensitivity analysis was performed to evaluate the effect of various outcome probabilities on the base-case analysis. Each clinical parameter varied from the lowest to the highest values as suggested in the literature, whereas other parameters remained constant. Because TT?pCND would cost more than TT alone, a negative incremental effectiveness meant TT alone was dominant. In the multivariate sensitivity analysis, total morbidity was assumed to be the same between the two strategies. A threshold analysis was undertaken to capture the threshold clinical values at which the ICER of TT?pCND relative to TT alone became zero (cost equivalence) or infinity (QALY equivalence). The range of threshold analysis was considerably expanded by adopting the theoretical range from 0 to 100 %. Table 2 shows the results of base-case analysis. After a 20-year period, each patient with TT?pCND spent an extra US$34.25 but also gained an additional 0.323 QALYs over TT alone. Therefore, following the base-case assumptions and model inputs, the TT?pCND was more costly but was also more effective than TT alone in the institution's perspective. The ICER of US$105.97 for TT?pCND relative to TT alone was far below the recommended threshold of US$50,000 per QALY. Table 2 shows the univariate and multivariate sensitivity analyses. No change in the conclusion was observed when key parameters such as complication rates and RAI were varied. Varying these parameters still yielded positive ICERs, thus implying that TT?pCND remained cost-effective or cost-saving. TT alone became cost-effective only when annualized central or central and lateral recurrence rates under this strategy decreased to zero or when the annualized central or lateral recurrence rates under the TT?pCND strategy increased to 0.82 and 1.57 %, respectively. Varying the number of year cycles or discount rate did not change the conclusion. Figure 1 shows the changes in ICER for TT?pCND relative to TT alone over a 50-year period. ICER reached below the threshold of US$50,000 per QALY from 9 years onward. In the multivariate sensitivity analysis, regardless of the actual value, as long as both strategies had equal total morbidity, TT?pCND was favored. Table 3 shows the results of the threshold analysis. To make TT alone cost-saving, there were 7 possible scenarios: annualized central recurrence in TT alone reduced from 0.63 to B0.17 %, annualized central and lateral recurrence in TT alone reduced from 0.56 to B0.08 %, permanent vocal cord palsy (VCP) in TT?pCND increased from 1.70 to C6.61 %, permanent hypoparathyroidism in TT?pCND increased from 1.47 to C6.38 %, annualized central recurrence in TT?pCND increased from 0.22 to C0.71 %, annualized lateral recurrence in TT?pCND increased from 0.36 to C1.03 %, or annualized central and lateral recurrence in TT?pCND increased from 0.29 to C0.94 %. However, there were many more possible scenarios to render TT?pCND cost-saving. Still, in terms of surgical morbidity, TT?pCND became costsaving if the associated permanent VCP could be kept B1.37 % or the permanent hypoparathyroidism could be kept B1.20 %. TT?pCND was also cost-saving when postoperative RAI use was reduced from 76.87 to B73.64 %.
RESULTS
Base-Case Analysis
Sensitivity Analysis
DISCUSSION
Performing routine pCND at the time of TT for cN0 PTC is controversial, and this is reflected in the revised American Thyroid Association guideline, which recommends that pCND ''may be performed in patients with clinically uninvolved central neck lymph nodes especially for advanced primary tumors (T3 or T4)''. 9 Unlike studies that compared surgical outcomes, our study aimed to compare the long-term cost-effectiveness between the two strategies. [27] [28] [29] To our knowledge, there has been only one published study that compared cost-effectiveness, and in that study, the authors concluded that TT?pCND was more costly and less effective (i.e., less cost-effective) than TT alone. 12 In contrast, although we did find TT?pCND to be more costly, it was more effective in the longer term. In our base analysis, TT?pCND was more cost-effective than TT alone at 20 years. The ICER of TT?pCND relative to TT alone was US$105.97 per QALY, which was well below the recommended threshold of US$50,000 per QALY, and from the sensitivity analysis, the ICER reached below the recommended threshold 9 years after surgery (Fig. 1) . These findings could be explained by the fact that patients in TT?pCND experienced less LR over time (Fig. 2) , and that led to fewer expensive reoperations, fewer reoperation complications, and a gain in QALY over time. However, our study had some notable differences from the previous study. 12 First, outcome probabilities were derived from a comprehensive literature search. Second, our quality adjustment factors or utility scores were derived from studies on thyroid disease only. Third, to provide a more realistic model, each LR was categorized into one of three locations, namely, central, lateral, and central and lateral compartments, because each compartment-oriented reoperation is associated with its own unique outcomes and costs. Fourth, instead of assuming the overall lifetime recurrence risk as the total recurrence risk over the first 5 years, we annualized recurrence risk on the basis of each of three compartments from previous studies.
Clinical Implications
On the basis of our analyses, several implications are relevant to clinicians. First, because TT?pCND becomes costeffective only 9 years after surgery, it is probably not worthwhile to perform pCND on patients with a life expectancy \9 years (such as the elderly or those with life-limiting comorbidities) because cost-effectiveness is not going to be achievable. Second, our data force each individual surgeon to consider what difference he or she could achieve by adding pCND at the time of TT. Our model showed that TT?pCND is cost-effective if it can reduce the 10-year LR rate by 7 or 0.7 % per year (from 1.57 to 0.87 %), so, for a lower risk reduction, TT?pCND would be less cost-effective or even become not cost-effective. Third, our data suggest that permanent surgical morbidities from TT?pCND play a significant role in the cost-effectiveness of TT?pCND. On the basis of our analyses, TT?pCND is cost-effective only if the associated permanent VCP can be kept\2.51 % or permanent hypoparathyroidism \5.88 %, so if any one of these permanent surgical morbidities is higher, TT alone could become cost-saving (Table 3) .
From the threshold analyses, although there were seven possible scenarios that could render TT alone cost-saving, they were either clinically impossible or unlikely to happen. Five of them were considered clinically impossible because all involved having annualized central or central and lateral compartment recurrences in TT alone less than in TT?pCND (0.17 vs. 0.22 and 0.08 vs. 0.29 %, respectively), and vice versa. However, because TT?pCND is already a TT, it could not possibly have a higher LR rate. The other 2 scenarios were clinically possible but unlikely. The first was if the permanent VCP rate under the TT?pCND strategy increased from 1.70 to C6.61 % while, under the TT-alone strategy, it was kept at FIG. 1 One way-sensitivity analysis of the incremental cost-effectiveness ratio (ICER) of total thyroidectomy ? prophylactic central neck dissection (TT?pCND) over total thyroidectomy alone (TT alone) as a function of time from primary operation (in years). The dashed line represents the US$50,000 per QALY threshold for costeffectiveness. After 9 years, TT?pCND became cost-effective 1.22 %. Although this was possible because pCND involved greater surgical dissection around the recurrent laryngeal nerve, an experienced surgeon is unlikely to cause a 3.9 times higher recurrent laryngeal nerve injury rate than with the same procedure without pCND. Similarly, an experienced surgeon is unlikely to cause a 7.5 times higher permanent hypoparathyroidism rate than with the same procedure without pCND (C6.38 vs. 0.85 %).
However, despite these results, we do acknowledge several shortcomings. First, some of the assumptions might have been oversimplified. For example, in many centers, not every patient with proven LR requires treatment, and even if treatment is indicated, there are other nonsurgical options, such as ethanol injection or radiofrequency ablation. Therefore, the actual cost of reoperations under both strategies might actually be substantially less, and that would have favored TT alone in the long-term. Furthermore, data suggest that the LR rate is probably nonlinear and is high only during the initial 5-10 years. 30 Therefore, our model might have overestimated the difference in LR between the two strategies and favored TT?pCND over time. Another example of oversimplification was to assume one LR followed by one reoperation per patient, because up to 10 % of patients with first-time LR are expected to require more than one reoperation. 31, 32 However, given the higher risk of LR in TT alone, this would have further favored the TT?pCND strategy. Second, despite a comprehensive literature search, selection and publication biases could not be completely ruled out because none of the studies examined was a prospective randomized study.
CONCLUSION
In the institution's perspective, TT?pCND was more cost-effective than TT alone for low-risk PTC in the longterm. It began to become cost-effective after 9 years from 
APPENDIX
See Fig. 3 .
FIG. 3 The Markov decision tree
